Effectiveness of nucleic acid polymers treatment in chronic viral hepatitis B HBeAg negative
Keywords:
viral hepatitis B, treatment, REP-2139-Ca, PegasysAbstract
In the clinical study there were 40 patients with chronic viral hepatitis B, negative HBeAg, divided into two groups of 20 patients each (the experimental group and the adaptive comparative control group), for a period of 24 weeks with Tenofovir 245 mg daily, and in the experimental group from the 25th week, Rep-2139 Mg was administered to 10 patients and Rep-2165 Mg to another 10 patients, 250 mg intravenously in slow infusion together with Pegasys 180 mg s.c. weekly and Tenofovir 245 mg daily for 48 weeks, the total duration of treatment being 72 weeks. The diagnosis was established on the basis of anamnestic, clinical, biochemical, molecular biological, serological and imaging data, by excluding hepatitis C and D virus, cytomegalic infection and HIV infection. In the adaptive comparative control group at week 25, Pegasys 180mg s.c. is administered. weekly, together with Tenofovir 245 mg daily, for 48 weeks, and from the 49th week REP 2139-Mg (in 10 patients), REP 2165-Mg (in another 10 patients) cit 250mg 2 intravenously in slow infusion is added together with Pegasys 180mg s.c. weekly and Tenofovir 245 mg daily for 48 weeks. The duration of treatment in the adaptive control group was 96 weeks. The treatment was well tolerated, HBsAg-antiHBs seroconversion was found during the 48-week treatment in 15 of 20 patients in the experimental group and in 12 of 20 in the adaptive comparative control group.
References
1. Bazinet M. et al. Journal of Hepatology 2020;73:S142. https://doi.org/10.1016/S0168-8278(20)30793-5
2. Blanchet M. et al. earch2019;164:97-105. https://doi.org/10.1016/j.antiviral.2019.02.009
3. Boulon R. et al. earch 2020:104853. https://doi.org/10.1016/j.antiviral.2020.104853
4. Choi H. J. et al. Journal of Hepatology 2020;73:714-715. https://doi.org/10.1016/j.jhep.2020.04.007
5. Chow N., Wong D., Lai C., Mak L., Fung J., Ma H., Lei M. et al. Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion. icaliouseases2022. https://doi.org/10.1093/cid/ciac383
6. Shekhtman L., Cotler S., Hershkovich L., Uprichard S., Bazinet M., Pantea V., Cebotarescu V. et al. Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg. entificorts2020;10:7837. https://doi.org/10.1038/s41598-020-64122-0
7. World Health Organization. Interim guidance for country validation of viral hepatitis elimination. Licence: CC BY-NC-SA 3.0 IGO. In; 2021
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
